Cargando…

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

OBJECTIVES: The purpose of this study was to carry out systematic review of the literature and meta-analysis to evaluate the diagnostic utility of cerebrospinal fluid (CSF) levels of the 42 amino acid form of amyloid-beta (Aβ(1–42)) as a biomarker for differentiating Alzheimer’s disease (AD) from no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mo, Jin-A, Lim, Ju-Hee, Sul, Ah-Ram, Lee, Min, Youn, Young Chul, Kim, Hee-Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339391/ https://www.ncbi.nlm.nih.gov/pubmed/25710596 http://dx.doi.org/10.1371/journal.pone.0116802

Ejemplares similares

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients
por: Kim, Hyun Jae, et al.
Publicado: (2019)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease
por: Kang, Ju-Hee
Publicado: (2016)

Lower Cerebrospinal Fluid Amyloid-β(42) Predicts Sooner Time to Antipsychotic Use in Alzheimer’s Disease
por: Cahan, Joshua G., et al.
Publicado: (2023)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease
por: Kaiser, Elmar, et al.
Publicado: (2011)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
por: Stroffolini, Giacomo, et al.
Publicado: (2021)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
por: Lee, Jongmin, et al.
Publicado: (2020)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
por: Müller, Ebba Gløersen, et al.
Publicado: (2019)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid
por: Yang, Ting, et al.
Publicado: (2019)

The Cerebrospinal Fluid Aβ(1–42)/Aβ(1–40) Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
por: Niemantsverdriet, Ellis, et al.
Publicado: (2017)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Jia, Longfei, et al.
Publicado: (2021)

Aβ42 as a Biomarker of Alzheimer’s Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
por: Boschi, Silvia, et al.
Publicado: (2022)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
por: Introna, Alessandro, et al.
Publicado: (2021)

Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease
por: De Kort, Anna M., et al.
Publicado: (2021)

The Relationship between Different Assays for Detection and Quantification of Amyloid Beta 42 in Human Cerebrospinal Fluid
por: Ellis, Teresa A., et al.
Publicado: (2012)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ(42,) in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents
por: Kounnas, Maria Z., et al.
Publicado: (2016)

High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis
por: Sturchio, Andrea, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
por: Park, Sun Ah, et al.
Publicado: (2015)

Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Maftei, Madalina, et al.
Publicado: (2013)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
por: Park, Sun Ah, et al.
Publicado: (2017)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease
por: Sun, Hao-Lun, et al.
Publicado: (2018)

Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele
por: Padayachee, E.R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_283lmsst71lhs20842babldgjn